Sulfacetamide Sodium and Prednisolone Sodium Phosphate Ophthalmic Solution is a sterile topical ophthalmic solution combining an anti-infective and an adrenocortical steroid.
Sulfacetamide sodium and prednisolone sodium phosphate ophthalmic solution is indicated for corticosteroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where superficial bacterial ocular infection or a risk of bacterial ocular infection exists.
Ocular corticosteroids are indicated in inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe where the inherent risk of corticosteroid use in certain infective conjunctivitides is accepted to obtain diminution in edema and inflammation. They are also indicated in chronic anterior uveitis and corneal injury from chemical, radiation, or thermal burns or penetration of foreign bodies.
The use of a combination drug with an anti-infective component is indicated where the risk of superficial ocular infection is high or where there is an expectation that potentially dangerous numbers of bacteria will be present in the eye.
The particular anti-infective drug in this product is active against the following common bacterial eye pathogens: Escherichia coli, Staphylococcus aureus, Streptococcus pneumoniae, Streptococcus (viridans group), Haemophilus influenzae,Klebsiella species, and Enterobacter species.
This product does not provide adequate coverage against: Neisseria species, Serratia marcescens.
A significant percentage of staphylococcal isolates are completely resistant to sulfa drugs.
Clinical Trials Related to Sulfacetamide and Prednisolone (Sulfacetamide / Prednisolone Ophthalmic)
Intraductal Meibomian Gland Probing Trial [Active, not recruiting]
In this research study, the investigators are looking at the effects of Meibomian Gland
Probing (MGP) versus a sham (fake) procedure in patients with refractory MGD who have
already tried traditional management with no success in resolving their clinical signs (as
seen by their ophthalmologist) or their symptoms.
The investigators are also evaluating the effects of using two (2) post-procedural
medication treatments: Blephamide or GenTeal PM Night-Time to determine if treatment after
the MGP procedure has an effect on its outcome.
Patients Response to Early Switch To Oral:Osteomyelitis Study [Not yet recruiting]
Based on the current literature, investigators hypothesize that patients with osteomyelitis
who are treated with the standard approach of intravenous antibiotics for the full duration
of therapy will have the same clinical outcomes as patients treated with the experimental
approach of intravenous antibiotics with early switch to oral antibiotics.
The primary objective of this study is to compare patients with osteomyelitis treated with
the standard approach of intravenous antibiotics for the full duration of therapy versus
patients treated with intravenous antibiotics with an early switch to oral antibiotics in
relation to clinical outcomes at 12 months after discontinuation of antibiotic therapy.
Secondary objectives of the study include the evaluation of adverse events related to the
use of antibiotics as well as the cost of care evaluated from the hospital perspective.
Effects of Hyperbaric Oxygen Therapy on Surgical Wound Healing [Enrolling by invitation]
The aim of this study is to test the effect of Hyperbaric Oxygen Therapy) HBOT (100% oxygen;
2. 0 ATA; 90 minute total exposure) and compare against a hyperbaric sham treatment (HBST)
(patient's breathing room air; 2. 0 ATA; 90 minute exposure) in reducing edema and
ecchymosis. HBOT will be applied as a single pre-operative and a single post-operative
treatment for patients undergoing eyelid surgery. Briefly, patients will be exposed to HBOT
2-4 hours prior to undergoing surgery, 2-4 hours post-surgery and healing will be assessed
at day 3, 10, 21, 30 & 90 days after surgery. Edema and ecchymosis will be assessed in a
time series to determine the extent that HBOT reduces these clinical signs. The primary
null hypothesis to test will be that no differences in scores will exist between treatment
and control at day 3, 10 & 21 post-surgery. A secondary null hypothesis to test is the time
required to change a score will be no different between the two groups.
HBOT=hyperbaric oxygen therapy; HBST=hyperbaric sham treatment
The Effect of Sodium Thiosulfate Eardrops on Hearing Loss in Patients Who Receive Cisplatin Therapy [Terminated]
This is a pilot, randomized, self-controlled study of the effects of intratympanic sodium
thiosulfate (STS) on the degree of hearing loss in patients receiving cisplatin therapy.
Sodium thiosulfate is an inactive ingredient contained in sulfacetamide ophthalmic solution
which is used routinely as an otic solution delivered to the middle ear space.
The hypothesis of this study is that local administration of sodium thiosulfate (STS) will
result in improved hearing compared to ears not receiving the study drug in patients
receiving systemic cisplatin therapy.
ORCA - Oracea® for Rosacea: A Community-based Assessment [Completed]
The objective of this study is to assess the effectiveness, safety, subject satisfaction and
quality of life with Oracea® when used as monotherapy or as add-on therapy to existing
topical regimens for the treatment of rosacea.
Page last updated: 2014-02-10